Results 201 to 210 of about 85,599,608 (253)

Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond

Obesity Reviews, EarlyView.
ABSTRACT Although there are conflicting clinical data on the efficacy of weight reduction in reducing secondary events in patients with comorbid overweight and obesity (OAO) and cardiovascular disease (CVD), there is excellent epidemiological and biological evidence of a cause–effect relationship between OAO, CVD, and other systemic complications ...
Wael Almahmeed, Juan S. Barajas‐Gamboa, Mohammad Zubaid, Ebaa Al Ozairi, Abdullah Shehab, Khalid Al‐Rasadi, Charbel Abi Khalil, Noor Al Busaidi, Fahad Al Sindi, Zuhier Awan, Tomader Ali, Khaldoon Al‐Humood, Fatheya Al Awadi, Mohammed Al Hadad, Manal Al Kindi, Khalid Al Habib, Khalid Al Waili, Maryam Alsaeed, Adel Tash, Hani Sabbour   +19 more
wiley   +1 more source

A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young Adults. [PDF]

J Endocr Soc
Laffel LM, Danne T, Klingensmith GJ, Schueler E, Tartakovsky I, Nessralla L, Zeitler P, Willi S.   +7 more
europepmc   +1 more source

Toward “Obesityomics”: Domain‐Specific Omics in Precision Obesity Medicine with a Brief AI Perspective

Obesity Reviews, EarlyView.
ABSTRACT Background Obesity's global rise has outpaced the effectiveness of “one‐size‐fits‐all” prevention and treatment strategies. The promise of precision medicine lies in addressing the etiological and biological diversity of obesity and transforming it into actionable endotypes.
Nadia Abu Samra, Sara G. I. Suliman, Mohammed Al‐Hadad, Dorret I. Boomsma, Fadwa Alhantoobi, Maithah Alsamahi, Haneen Abufarajallah, Alia Al Tikriti, Zeyar Aung, Selena Richards, Abdulrahim Sajini, Mira Mousa, Fatima Sulaiman, Wael Osman   +13 more
wiley   +1 more source

AI/ML-Driven DPP-4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps. [PDF]

Arch Pharm (Weinheim)
Manhas A, Dutta R, Piotto S, Amin SA.
europepmc   +1 more source

Effect of a DPP-4 Inhibitor on Orthodontic Tooth Movement and Associated Root Resorption. [PDF]

Biomed Res Int, 2020
Qi J, Kitaura H, Shen WR, Ogawa S, Ohori F, Noguchi T, Marahleh A, Nara Y, Adya P, Mizoguchi I.   +9 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment

Obesity Reviews, EarlyView.
ABSTRACT Obesity is a well‐established risk factor for numerous cancers, with body habitus, especially central adiposity, contributing to increased cancer incidence and worse prognosis. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed to treat Type 2 diabetes, have rapidly gained prominence as powerful anti‐obesity agents due ...
Lorne J. Hofseth, E. Angela Murphy, Mary C. Playdon, Liza Makowski, Anna R. Ibele, Ciaran M. Fairman, James R. Hebert   +6 more
wiley   +1 more source

Assessment of Knowledge and General Attitudes of Primary Care Physicians Toward Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Drugs in the Management of Type 2 Diabetes Mellitus in the Qassim Region. [PDF]

Cureus
Aljulajil F, Rabbani U.
europepmc   +1 more source

The impacts of dipeptidyl- peptidase 4 (DPP-4) inhibitors on common female malignancies: A systematic review

The inhibition of dipeptidyl- peptidase 4 (DPP-4) is an essential therapy for controlling hyperglycemia in patients with type 2 diabetes (T2DM). However, the role of DPP-4 in cancer is not yet clear, with some studies suggesting that it may either ...
A Niazmand (21482669), N Vatandoost (21445100), S Jafarpour (21445097), R Salehi (20956334), R Nedaeinia (20956331), Gordon Ferns (4464037), S Safabakhsh (16330263), M Kolahdouz (21482672)   +7 more
core  

Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai, Gil Caspi, Akhilanand Chaurasia, Gavriel Chaushu, Daya Masri, Ehud Jonas   +5 more
wiley   +1 more source

Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. [PDF]

Diabetes Obes Metab
Kaku K, Shimoda M, Osonoi T, Iwamoto M, Kaneto H.   +4 more
europepmc   +1 more source